Latest Market News

Equity Story Group reports a strong quarter for its Growth Fund but faces setbacks with the termination of the Baker Young acquisition. The company is now pursuing a significant capital raise and has restructured its board to drive future growth.

AVADA Group Limited reported a revenue increase in Q1 FY26 despite ending a major contract, alongside a significant reduction in operating cash outflows and ongoing debt repayments.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

AGL Energy has agreed to purchase four new gas turbines for $185 million to develop the Kwinana Swift Gas 2 project, securing 176MW of reserve capacity to support Western Australia’s energy transition.

Articore Group has initiated an on-market share buy-back of up to 10% of its issued capital, signaling renewed confidence in its turnaround and long-term growth prospects.

QMines Limited has completed the acquisition of the Mt Mackenzie gold-silver project, upgraded its resource base, and advanced drilling at Develin Creek, supported by a $9 million capital raise to fund exploration and development.

Pinnacle Minerals has raised $2.2 million to fund its strategic expansion into the US critical minerals sector, acquiring eight new projects and commencing exploration activities in Idaho and Washington State.

Cluey Ltd reported a stable Q1 FY26 revenue of $7.4 million alongside its strongest-ever underlying EBITDA, as it accelerates investment in AI-driven educational products set to launch in 2026.

Knosys Limited reported robust Q1 FY26 results with $3.5 million in cash receipts and a steady $9.5 million annual recurring revenue, while advancing its AI-driven Libero X product and appointing a new Chair.

Cluey Ltd has reported its strongest-ever underlying EBITDA alongside improved cash flow, while ramping up investments in AI-powered product development set to launch in 2026.

Resmed Inc. kicked off fiscal 2026 with robust 9% revenue growth and a notable 290 basis points gross margin expansion, signaling strong momentum in home healthcare innovation. The company also declared a $0.60 dividend and executed a $150 million share buyback, underscoring confidence in its strategic direction.

Bio-Gene Technology Limited reports significant progress in Q1 FY26, unveiling new product opportunities and positive efficacy data, alongside securing US Department of Defense grants.